Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vorinostat + Bortezomib in Relapsed/Refractory Multiple Myeloma
NCT00773838Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Dec 2008
- Primary completion
- May 2011
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of vorinostat in multiple myeloma (MM), sponsored by Merck & Co. Primary endpoint: Objective Response Rate at 30 months. Started Dec 2008; status: completed.
02
Drugs
vorinostat
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT00773838.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00773838.